Besides, four sex-biased exon skipping events in cancer therapeutic target genes (FDPS, FGFR1, CDK4, and IMPDH2) could cause the loss of partial protein function, which may contribute to a differential drug response rate in male and female patients (Fig. 8A). This evidence concerns the gene FGFR1 and cancer.